OptiNose, Inc. (OPTN)
NASDAQ: OPTN · IEX Real-Time Price · USD
1.060
-0.020 (-1.85%)
At close: Jul 19, 2024, 4:30 PM
1.030
-0.030 (-2.83%)
Pre-market: Jul 22, 2024, 4:10 AM EDT
OptiNose Employees
OptiNose had 132 employees as of December 31, 2023. The number of employees decreased by 9 or -6.38% compared to the previous year.
Employees
132
Change (1Y)
-9
Growth (1Y)
-6.38%
Revenue / Employee
$560,773
Profits / Employee
-$232,992
Market Cap
153.53M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
High Tide | 1,550 |
Rani Therapeutics Holdings | 140 |
Kodiak Sciences | 111 |
Vaxart | 109 |
Capricor Therapeutics | 102 |
Assertio Holdings | 53 |
Achieve Life Sciences | 22 |
Galectin Therapeutics | 14 |
OPTN News
- 25 days ago - Expanded Access to XHANCE with Addition to National Commercial Formularies - GlobeNewsWire
- 2 months ago - Optinose to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ - GlobeNewsWire
- 2 months ago - Optinose Reports First Quarter 2024 Financial Results and Recent Operational Highlights - GlobeNewsWire
- 2 months ago - Optinose Announces Reporting Date for First Quarter 2024 Financial Results - GlobeNewsWire
- 3 months ago - Optinose Provides Corporate Update on XHANCE Launch and Outlook and Announces Preliminary First Quarter 2024 XHANCE Net Revenue of $14.9 million - GlobeNewsWire
- 3 months ago - Optinose to Present at the Needham Virtual Healthcare Conference - GlobeNewsWire
- 4 months ago - XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal Polyps - GlobeNewsWire
- 4 months ago - Optinose Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights - GlobeNewsWire